does glp 1 interfere with anesthesia AAOMS may update guide for GLP-1 receptor agonist users GLP-1 Receptor Agonists And Aspiration

Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol

Community protocols document potency degradation at room temperature

KLOW is providedexclusively for laboratory and research purposes

While the vote is only advisory and must still go through a formal rulemaking process, it could give patients the mistaken impression that these unapproved peptides are FDA-endorsed and accelerate their use through compounding pharmacies